Scholarlink

Background <p>The rise of multidrug-resistant tuberculosis (MDR-TB) poses a significant challenge to global health. This study aimed to develop a novel drug delivery system using mesoporous silica nanoparticles (MSNPs) loaded with dual drug conjugates to combat MDR-TB.</p> Objective <p>To design, optimize, and evaluate MSNPs loaded with dual drug conjugates for enhanced treatment of MDR-TB.</p> Methods <p>Two dual drug conjugates, D-Cycloserine-Chloroacetyl chloride-Moxifloxacin (DCM) and D-Cycloserine-Succinyl chloride-Moxifloxacin (DSM), were synthesized via nucleophilic substitution reactions. The conjugates were evaluated for hydrolysability and loaded into MSNPs, which were optimized using Design Expert software. The MSNPs were characterized using FTIR, NMR, particle size analysis, zeta potential measurements, and SEM. In vitro drug release, in vivo pharmacokinetic studies, and in vitro microbiological investigations against&#xa0;<i>M. tuberculosis</i>&#xa0;H37Rv were conducted.</p> Results <p>The optimized MSNPs exhibited desirable characteristics, including a uniform mesoporous structure, high drug loading, controlled release, and enhanced bioavailability. DSM-loaded MSNPs demonstrated superior synergistic inhibitory activity against&#xa0;<i>M. tuberculosis</i>&#xa0;H37Rv compared to DCM and the free drug mixture.</p> Conclusion <p>This study highlights the potential of MSNPs loaded with dual drug conjugates, particularly DSM, as an effective strategy for MDR-TB treatment. This approach offers enhanced drug delivery, synergistic activity, and improved bioavailability, potentially overcoming challenges associated with MDR-TB.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Conjugate Delivery of D-Cycloserine and Moxifloxacin via Hydrolysable Cross Linkers -Mesoporous Silica Nanoparticles for Synergistic Effect on Multiple Drug Resistant on Tuberculosis

  • 期刊论文

  • 发表日期：

    2025年4月4日

查看全文
  • B. Nagashubha,
  • Lalit Kumar,
  • Azger Dusthackeer VN,
  • Y. Padmanabha Reddy

摘要

Background

The rise of multidrug-resistant tuberculosis (MDR-TB) poses a significant challenge to global health. This study aimed to develop a novel drug delivery system using mesoporous silica nanoparticles (MSNPs) loaded with dual drug conjugates to combat MDR-TB.

Objective

To design, optimize, and evaluate MSNPs loaded with dual drug conjugates for enhanced treatment of MDR-TB.

Methods

Two dual drug conjugates, D-Cycloserine-Chloroacetyl chloride-Moxifloxacin (DCM) and D-Cycloserine-Succinyl chloride-Moxifloxacin (DSM), were synthesized via nucleophilic substitution reactions. The conjugates were evaluated for hydrolysability and loaded into MSNPs, which were optimized using Design Expert software. The MSNPs were characterized using FTIR, NMR, particle size analysis, zeta potential measurements, and SEM. In vitro drug release, in vivo pharmacokinetic studies, and in vitro microbiological investigations against M. tuberculosis H37Rv were conducted.

Results

The optimized MSNPs exhibited desirable characteristics, including a uniform mesoporous structure, high drug loading, controlled release, and enhanced bioavailability. DSM-loaded MSNPs demonstrated superior synergistic inhibitory activity against M. tuberculosis H37Rv compared to DCM and the free drug mixture.

Conclusion

This study highlights the potential of MSNPs loaded with dual drug conjugates, particularly DSM, as an effective strategy for MDR-TB treatment. This approach offers enhanced drug delivery, synergistic activity, and improved bioavailability, potentially overcoming challenges associated with MDR-TB.